Protecting retinal cells could save sight

Article

A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.

A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.

The breakdown of retinal cells known as photoreceptors is common to several diseases that cause blindness. In the diseases the researchers studied the photoreceptors were dying from a variety of causes, but common to all cases was the activation of a family of molecules called CREB1/ATF1. The team then attempted to determine if the molecules were contributing to the cell death or were being activated in an attempt to prolong cell life.

Studying retinas treated with a drug known to preserve photoreceptors, the researchers found much higher levels of CREB1/ATF1, suggesting the molecules act as part of the protective mechanism.

"Not only did we find that the drug activated the novel CREB1/ATF1 photoreceptor pathway, but we found that this activation was caused by stress," said Caroline Zeiss, associate professor of comparative medicine and ophthalmology at Yale School of Medicine, USA, in a statement. "This suggests that CREB/ATF1 may be an innate protective response that could be used to achieve broad spectrum preservation of the retina."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.